vTv Therapeutics Company Profile (NASDAQ:VTVT)

About vTv Therapeutics

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTVT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.47
  • 50 Day Moving Average: $5.44
  • 200 Day Moving Average: $5.80
  • 52-Week Range: $4.65 - $7.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.01
  • P/E Growth: 0.00
  • Market Cap: $53.02M
  • Outstanding Shares: 9,693,000
  • Beta: 0.99
Profitability:
  • Net Margins: -1,882.12%
  • Return on Assets: -21.15%
Debt:
  • Current Ratio: 4.93%
  • Quick Ratio: 4.93%
Additional Links:
Companies Related to vTv Therapeutics:

Analyst Ratings

Consensus Ratings for vTv Therapeutics (NASDAQ:VTVT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (206.69% upside)

Analysts' Ratings History for vTv Therapeutics (NASDAQ:VTVT)
Show:
DateFirmActionRatingPrice TargetDetails
12/18/2016Canaccord GenuitySet Price TargetBuy$15.00View Rating Details
12/16/2016HC WainwrightReiterated RatingBuy$13.00View Rating Details
12/15/2016Stifel NicolausSet Price TargetBuy$14.00View Rating Details
10/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00View Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for vTv Therapeutics (NASDAQ:VTVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
5/12/2016Q1($0.54)($0.42)ViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-1.79 EPS

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.17%
Institutional Ownership Percentage: 12.18%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
DateHeadline
News IconSell-side is Weighing in on vTv Therapeutics Inc (NASDAQ:VTVT) Earnings & Targets - Aiken Advocate (NASDAQ:VTVT)
aikenadvocate.com - February 17 at 7:00 AM
News IconSell-Side Offering Their Recommendations on vTv Therapeutics Inc. (NASDAQ:VTVT) - Rockville Register (NASDAQ:VTVT)
rockvilleregister.com - February 14 at 6:59 AM
News IconAnalysts Take the Wheel on vTv Therapeutics Inc (NASDAQ:VTVT) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:VTVT)
aikenadvocate.com - February 2 at 6:43 AM
News IconInvestor Guide: Check on Technical Levels for Vtv Therapeutics Inc (VTVT) - Sherwood Daily (NASDAQ:VTVT)
sherwooddaily.com - February 2 at 6:43 AM
News IconIndicator Level Summary for Vtv Therapeutics Inc (VTVT) - Sherwood Daily (NASDAQ:VTVT)
sherwooddaily.com - January 27 at 8:58 PM
finance.yahoo.com logovTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher (NASDAQ:VTVT)
finance.yahoo.com - January 25 at 4:27 PM
News IconVTv Therapeutics Inc. (VTVT) Under Analyst Spotlight - UK Market News (NASDAQ:VTVT)
www.ukmarketnews.co.uk - January 24 at 3:25 PM
News IconEarnings in Full Force, Analysts Take Aim at vTv Therapeutics Inc (NASDAQ:VTVT) - Wall Street Beacon (NASDAQ:VTVT)
wsbeacon.com - January 24 at 3:25 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: vTv Therapeutics Inc. (NASDAQ:VTVT) - Wall Street Beacon (NASDAQ:VTVT)
wsbeacon.com - January 22 at 7:05 AM
News IconAnalysts Take: vTv Therapeutics Inc (NASDAQ:VTVT) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:VTVT)
aikenadvocate.com - January 19 at 4:02 PM
News IconStock Rating Sentiment Runner: Can analysts adopt a bullish outlook for vTv Therapeutics Inc (NASDAQ:VTVT)? - Fair View Times (NASDAQ:VTVT)
fairviewtimes.com - January 17 at 3:50 PM
News IconTechnical Tracker: Watching Shares of Vtv Therapeutics Inc (VTVT) - Sherwood Daily (NASDAQ:VTVT)
sherwooddaily.com - January 17 at 3:50 PM
News IconWill The Needle Move For vTv Therapeutics Inc (NASDAQ:VTVT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VTVT)
wsbeacon.com - January 17 at 3:50 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: vTv ... - Wall Street Beacon (NASDAQ:VTVT)
wsbeacon.com - January 15 at 8:02 PM
News IconReady for an Upsurge? Analysts Chime in on vTv Therapeutics Inc. (NASDAQ:VTVT) - Prospect Journal (NASDAQ:VTVT)
prospectjournal.com - January 2 at 3:39 PM
News IconCan This Stock Gain Traction: vTv Therapeutics Inc. (NASDAQ:VTVT) - Prospect Journal (NASDAQ:VTVT)
prospectjournal.com - December 27 at 8:18 AM
News IconVTv Therapeutics Inc. (VTVT) Valuation According To Analysts - UK Market News (NASDAQ:VTVT)
www.ukmarketnews.co.uk - December 27 at 8:18 AM
News IconTop Stock With Upside & Growth Potential: vTv Therapeutics Inc. (NASDAQ:VTVT) - Prospect Journal (NASDAQ:VTVT)
prospectjournal.com - December 19 at 3:19 PM
marketexclusive.com logoAnalyst Activity – HC Wainwright Reiterates Buy on vTv Therapeutics (NASDAQ:VTVT) (NASDAQ:VTVT)
marketexclusive.com - December 18 at 4:28 AM
fxpips.com logoActive Stocks Gaining, Pre Market – WINS, EBMT, STRP, OKSB, EGHT, VTVT, CIVI (NASDAQ:VTVT)
www.fxpips.com - December 16 at 6:24 AM
4-traders.com logovTv Therapeutics : Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes (NASDAQ:VTVT)
www.4-traders.com - December 15 at 7:13 AM
News IconPotential Type 2 Diabetes Drug Boosts vTv Therapeutics (VTVT); Pier 1 Imports (PIR) Profit Exceeds Forecast (NASDAQ:VTVT)
galaxystocks.com - December 15 at 7:13 AM
us.rd.yahoo.com logovTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes (NASDAQ:VTVT)
us.rd.yahoo.com - December 15 at 7:13 AM
us.rd.yahoo.com logo4:33 pm vTv Therapeutics announces 'positve' data from its Phase 2 study evaluating TTP273 for the treatment of Type 2 diabetes; Oral small molecule GLP-1 receptor agonist met primary endpoint (NASDAQ:VTVT)
us.rd.yahoo.com - December 15 at 7:13 AM
News IconStock Watch: Indicators in View for Vtv Therapeutics Inc (VTVT) - Yankee Analysts (NASDAQ:VTVT)
yankeeanalysts.com - December 8 at 9:34 PM
News IconNew Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at th... (NASDAQ:VTVT)
ih.advfn.com - November 17 at 7:56 PM
streetinsider.com logovTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as PD Treatment at Upcoming Conference (NASDAQ:VTVT)
www.streetinsider.com - November 16 at 12:14 PM
finance.yahoo.com logoNew Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego (NASDAQ:VTVT)
finance.yahoo.com - November 16 at 12:14 PM
finance.yahoo.com logo9:15 am vTv Therapeutics to present new pre-clinical data on a vTv Therapeutics small molecule drug candidate against Parkinson's Disease (NASDAQ:VTVT)
finance.yahoo.com - November 16 at 12:14 PM
finance.yahoo.com logoCan JD.com (JD) Stock Surprise Investors in Q3 Earnings? (NASDAQ:VTVT)
finance.yahoo.com - November 14 at 12:34 PM
finance.yahoo.com logoVTV THERAPEUTICS INC. Financials (NASDAQ:VTVT)
finance.yahoo.com - November 10 at 8:20 PM
finance.yahoo.com logovTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences (NASDAQ:VTVT)
finance.yahoo.com - November 10 at 8:20 PM
capitalcube.com logoETF’s with exposure to vTv Therapeutics, Inc. : November 7, 2016 (NASDAQ:VTVT)
www.capitalcube.com - November 7 at 9:23 PM
capitalcube.com logovTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016 (NASDAQ:VTVT)
www.capitalcube.com - November 4 at 12:30 PM
sg.finance.yahoo.com logoVTv Therapeutics reports 3Q loss (NASDAQ:VTVT)
sg.finance.yahoo.com - November 3 at 12:39 PM
marketexclusive.com logovTv Therapeutics Inc (NASDAQ:VTVT) Files An 8-K (NASDAQ:VTVT)
marketexclusive.com - November 2 at 8:48 PM
publicnow.com logovTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights (NASDAQ:VTVT)
www.publicnow.com - November 2 at 8:48 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:VTVT)
biz.yahoo.com - November 2 at 8:48 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial (NASDAQ:VTVT)
biz.yahoo.com - October 31 at 8:48 AM
finance.yahoo.com logovTv Therapeutics to Present at Peptide Therapeutics Symposium (NASDAQ:VTVT)
finance.yahoo.com - October 24 at 7:39 PM
News IconvTv Therapeutics To Present At (NASDAQ:VTVT)
www.biospace.com - October 3 at 7:27 PM
News IconvTv Therapeutics to Present at Neuro Advance Boston (NASDAQ:VTVT)
ih.advfn.com - October 3 at 7:44 AM
finance.yahoo.com logovTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference (NASDAQ:VTVT)
finance.yahoo.com - September 8 at 11:57 AM
News IconvTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon ... (NASDAQ:VTVT)
www.biomedreports.com - September 7 at 11:55 AM
publicnow.com logovTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease (NASDAQ:VTVT)
www.publicnow.com - September 7 at 11:55 AM
News IconvTv Therapeutics To Present At The (NASDAQ:VTVT)
www.biospace.com - September 2 at 7:51 PM
finance.yahoo.com logovTv Therapeutics to Present at the International Psychogeriatric Association International Congress (NASDAQ:VTVT)
finance.yahoo.com - September 2 at 8:02 AM
publicnow.com logovTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes (NASDAQ:VTVT)
www.publicnow.com - August 16 at 11:33 AM
wsj.com logo[$$] Clinical Development News, Aug. 8-12 (NASDAQ:VTVT)
www.wsj.com - August 12 at 8:20 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VTVT)
biz.yahoo.com - August 11 at 11:40 AM

Social

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for vTv Therapeutics' stock. Their predictions range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' stock price to reach $16.50 in the next year.

When will vTv Therapeutics announce their earnings?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about vTv Therapeutics stock?

Here are some recent quotes from research analysts about vTv Therapeutics stock:

  • According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (2/15/2017)

  • HC Wainwright analysts commented, "We are more enthusiastic about the two diabetes drugs that should be ripe for partnering upon success in Phase 2. TTP399 completed a successful Phase 2b in August and TTP273 should have Phase 2b data in December, the nearest term catalyst," analyst Corey Davis wrote in a note.Related Link: vTV Therapeutics Completes Enrollment For PHase 2 TTP273 TrialOn the other hand, although Azeliragon could be "one of the next wave of promising Alzheimer's drugs," the analyst is not expecting the stock to move near term on this drug given the history and lack of data until 2018.The upcoming catalysts include TTP273 Phase 2 data in diabetes and publication of Phase 2 results from TTP399 in diabetes, both expected in late 2016. Also, potential partnerships on one or both of the diabetes drugs could also boost the stock.On the partnering front, Davis said larger firms such as the following would make a good fit:AstraZeneca plc (ADR) (NYSE: AZN).Boehringer Ingelheim Corporation.Eli Lilly and Co (NYSE: LLY).GlaxoSmithKline plc (ADR) (NYSE: GSK).Johnson & Johnson (NYSE: JNJ).Merck & Co., Inc. (NYSE: MRK).Novartis AG (ADR) (NYSE: NVS).Novo Nordisk A/S (ADR) (NYSE: NVO).Sanofi SA (ADR) (NYSE: SNY).Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY).Meanwhile, the analyst sees a potential upside of 81 percent in vTv shares with a $13 target price."Our target of $13 would only be a $425 million market cap. With some of the recent deals for diabetes drugs, a standard upfront milestone payment alone could allow the stock to reach our target," (9/26/2016)

Who owns vTv Therapeutics stock?

vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (9.83%), Alyeska Investment Group L.P. (2.20%), Piper Jaffray & Co (1.90%), Wall Street Associates (1.70%), State Street Corp (0.89%) and Renaissance Technologies LLC (0.63%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman.

Who sold vTv Therapeutics stock? Who is selling vTv Therapeutics stock?

vTv Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates and State Street Corp.

Who bought vTv Therapeutics stock? Who is buying vTv Therapeutics stock?

vTv Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P. and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman.

How do I buy vTv Therapeutics stock?

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of vTv Therapeutics stock cost?

One share of vTv Therapeutics stock can currently be purchased for approximately $5.38.

vTv Therapeutics (NASDAQ:VTVT) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Earnings History Chart

Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Dividend History Chart

Dividend Payments by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Last Updated on 2/22/2017 by MarketBeat.com Staff